Get the Stockscreener App
6.12
1.45%
-0.09
Dogwood Therapeutics Inc stock is traded at $6.12, with a volume of 75,868.
It is down -1.45% in the last 24 hours and up +6.99% over the past month.
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$6.21
Open:
$6.16
24h Volume:
75,868
Relative Volume:
0.11
Market Cap:
$181.93M
Revenue:
-
Net Income/Loss:
$-24.74M
P/E Ratio:
-0.3258
EPS:
-18.7859
Net Cash Flow:
$-15.75M
1W Performance:
-6.13%
1M Performance:
+6.99%
6M Performance:
+14.61%
1Y Performance:
+142.89%
1-Day Range:
$6.0895
$6.24
1-Week Range:
$6.08
$6.72
52-Week Range:
$1.87
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
6.12 | 184.61M | 0 | -24.74M | -15.75M | -18.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Can Dogwood Therapeutics Inc. stock outperform in 2025 bull market2025 Risk Factors & Low Drawdown Momentum Ideas - Newser
Why Dogwood Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Daily Technical Forecast Reports - Newser
Dogwood Therapeutics (Nasdaq: DWTX) files synthetic Halneuron IP, eyes 2045 exclusivity - Stock Titan
Dogwood Therapeutics (DWTX) Stock Analysis Report | Financials & Insights - Benzinga
Why retail investors favor Dogwood Therapeutics Inc. stockJuly 2025 Outlook & Capital Efficiency Focused Strategies - BỘ NỘI VỤ
Dogwood Therapeutics Inc enters equity distribution agreement with Northland SecuritiesSEC filing - marketscreener.com
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight - GlobeNewswire Inc.
[Form 4] Dogwood Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dogwood Therapeutics: Clinical Readout Looms As A Potential Game-Changer - RTTNews
What Institutional Trends Suggest About Pearl Polymers Limiteds DirectionSupport Zone Identification & High Return Capital Strategies - earlytimes.in
What analysts say about Dogwood Therapeutics Inc stockStock Valuation Metrics & Affordable Investment Portfolio - earlytimes.in
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge - MSN
Dogwood Therapeutics shareholders approve equity plan and business combination By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Approves Equity Plan Amid Business Merger - MSN
Dogwood Therapeutics shareholders approve equity plan and business combination - Investing.com
[8-K] Dogwood Therapeutics, Inc. Reports Material Event | DWTX SEC FilingForm 8-K - Stock Titan
DWTX: All five board proposals, including stock conversions and equity plan, were approved - TradingView
DWTX: All five board proposals, including stock conversions and an equity plan, were approved - TradingView
Is Dogwood Therapeutics Inc. stock positioned for long term growthJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com
How sentiment analysis helps forecast Dogwood Therapeutics Inc.Buy Signal & Safe Capital Preservation Plans - newser.com
Is Dogwood Therapeutics Inc. stock reversal real or fake2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
Published on: 2025-11-19 15:22:38 - newser.com
Order flow analysis tools used on Dogwood Therapeutics Inc.Rate Cut & Low Drawdown Trading Techniques - newser.com
How strong is Dogwood Therapeutics Inc. stock balance sheetJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - newser.com
Identifying reversal signals in Dogwood Therapeutics Inc.Sell Signal & Real-Time Buy Zone Alerts - newser.com
Can technical indicators confirm Dogwood Therapeutics Inc.’s reversalMarket Trend Report & Weekly Top Stock Performers List - newser.com
Will Dogwood Therapeutics Inc. stock recover faster than peersOil Prices & Free Risk Controlled Daily Trade Plans - newser.com
Smart tools for monitoring Dogwood Therapeutics Inc.’s price actionEarnings Growth Summary & Daily Technical Forecast Reports - newser.com
Using economic indicators to assess Dogwood Therapeutics Inc. potentialQuarterly Risk Review & Smart Money Movement Alerts - newser.com
Is Dogwood Therapeutics Inc. stock entering bullish territory2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Trend analysis for Dogwood Therapeutics Inc. this weekPortfolio Risk Report & Smart Swing Trading Alerts - newser.com
Will Dogwood Therapeutics Inc. stock deliver long term returnsQuarterly Trade Report & Expert Verified Stock Movement Alerts - newser.com
Why retail investors pile into Dogwood Therapeutics Inc. stock2025 Biggest Moves & AI Powered Buy/Sell Recommendations - newser.com
Institutional scanner results for Dogwood Therapeutics Inc.2025 AllTime Highs & Weekly High Return Opportunities - newser.com
Is Dogwood Therapeutics Inc. stock trading at a premium valuationIPO Watch & Target Return Focused Stock Picks - newser.com
Will Dogwood Therapeutics Inc. stock benefit from upcoming earnings reportsProfit Target & Capital Protection Trading Alerts - Fundação Cultural do Pará
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):